TACE or HAIC with targeted therapy and immunotherapy for liver cancer
Official title: Study of the Safety, Clinical Efficacy and Prognostic Factors of TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07658833 · Data updated 2026-11-12
This study tests whether adding targeted drugs and immunotherapy to TACE or HAIC helps people with unresectable hepatocellular carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Drugs / interventions | bevacizumab, pembrolizumab, sintilimab, teprotumumab, lenvatinib, apatinib, chemotherapy, immunotherapy |
| Locations | 1 site (Guangzhou, None Selected) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07658833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-80 with unresectable HCC, Child-Pugh A or B, ECOG 0-1, tumor diameter ≥7 cm, with IV/RA tumor thrombus, who have not had prior anti-tumor therapy.
✕Probably not a fit
Patients with poor liver function, other malignancies, autoimmune disorders, or contraindications to study therapies may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates safety, efficacy, and prognostic factors for combining transarterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) with targeted therapy and immunotherapy in patients with hepatocellular carcinoma. Outcomes include local tumor response, overall survival, prognostic indicators, and adverse events, with responses measured by mRECIST and AEs by CTCAE v5.0. Treatments may include agents such as lenvatinib, sorafenib, apatinib, bevacizumab, pembrolizumab, and others, used alone or in combination. Eligible participants are adults with unresectable HCC, adequate liver function, and specific tumor characteristics, enrolled at Sun Yat-sen Memorial Hospital, Guangzhou. The study is observational and does not specify a randomized design.
Why it matters
Potential benefit: If successful, patients could experience better tumor control and survival when combining these therapies.
How similar studies have gone: Prior studies in similar approaches suggesting safety and potential benefit, but the exact combination with TACE/HAIC and immunotherapy remains to be clarified.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 18-80 years * Eastern Cooperative Oncology Group (ECOG) performance status score \< 2 * maximum tumor diameter ≥ 7 cm * IVC/RA TT diagnosed by contrast-enhanced CT / MRI before study treatment * unresectable HCC (uHCC) confirmed by a specialized multidisciplinary team * liver function of Child-Pugh class A or B Exclusion Criteria: * with other malignancies * prior anti-tumor therapy * history of drug allergy * autoimmune diseases * digestive hemorrhage of any grade * insufficient renal, bone marrow, or coagulation function
Where it's running
-
Jiayan Ni
Guangzhou, None Selected, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
AI-guided treatment choices for advanced liver cancer
Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.
-
Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer
Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
MRI plus diffusion and CEST imaging to map liver cancer and its immune environment
This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.
-
Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC
This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.